Category: Cancer Research

Mikhail Blagosklonny: the Cure for Cancer and Anti-aging

Mikhail Blagosklonny is a renowned scientist and researcher. Mikhail has spent most of his career life researching about the causes and treatment of cancer and aging related problems. Professor Blagosklonny inventions have and will continue to be very helpful in the field of oncology. He has conducted numerous researches that have helped in the development of cancer medicines. Throughout his career life, Mikhail has earned the respect of many people for his outstanding research work. Blagosklonny has been a role model to many people especially his peers and students at Rosewell Cancer Institute in New York where he teaches oncology.Currently, Professor Mikhail is researching to establish the relationship between aging and cancer. It has been found out that cancer is more common to individuals above a certain age. The research work has attracted a lot of attention in the medical field especially on impactjournals.com. All Mikhail Blagosklonny research works are not only geared toward finding ways to treating cancer but also treating cancer effectively. The current cancer treatment method is usually painful and expensive to the ordinary citizen.

Also, researcher Blagosklonny is committed to developing a process in which cancerous cells can be removed from the body without damaging the normal cells. Healthy cells play a significant role towards the recovery of the mind and the body after the long period of cancer treatment.Apart from cancer, scientist Mikhail is a distinguished anti-aging condition researcher. Blagosklonny studied aging and cancer at the prestigious Rosswell Cancer Institute in New York. While at Rosswell Institute, Mikhail discovered that the target of rapamycin (TOR) is responsible for aging. TOR in a developing cell speeds up growth and cannot be stopped easily. This abnormal growth affects the cells and damages the body organs. As the effect of TOR continues to affect the cells and damage body organs, the number of tumor increases thus making people be at high risks of getting cancer as they grow old.

Mikhail Blagosklonny early life

Mikhail Blagosklonny was born in Russia but currently lives in New York, United States. He is widely recognized for his greatest contributions in the field of oncology. Researcher Blagosklonny studied at the First Pavlov State Medical University of St. Petersburg. It was in this institution where he acquired his medical degree in the field of internal medicine. He later earned his Ph.D. in experimental medicine and cardiology from the same university.After completing his studies, Mikhail worked for New York Medical College as the associate professor. In 2002, prof. Blagosklonny accepted a top position at the Ordway Research Institute where he served as a senior scientist, a position he held until 2009 when he was appointed as the professor of oncology at the prestigious Rosswell Park Center Institute.Despite being much involved with research work, Blagosklonny finds time to share his knowledge with other professionals in the medical field. He teaches doctors on the different kind of therapies that can be used to protect patient’s healthy cells from extensive damage among other topics through a medical journal called Oncotarget. Mikhail also acts as one of the chief editors of this journal.

Clay Siegall’s Passion For Conducting Cancer Research

In the last decade, Seattle Genetics made significant strides in the field of cancer research. Today, the company has recruited some of the leading researchers and scientists to undertake comprehensive studies on cancer and aging. The firm started as a small agency. With its continued progress in developing viable cancer therapies, Seattle Genetics has managed to expand the scope of its research to include aging-related diseases. Within five years of operations, Seattle Genetics’ stock price had tripled, indicating the firm’s impact in the industry.

Clay Siegall heads Seattle Genetics. Since he started his profession in biomedical studies, Clay has always been interested in improving the lives of cancer patients. He is a graduate of George Washington University where he earned his PhD in Genetics. He started his career at Bristol-Meyers Squibb Pharmaceuticals Research Institute by working as a senior research investigator. He rose through the ranks to become a principal scientist. Later, he joined the National Cancer Institute where he worked as a biotechnology and staff fellow.

Over the years, Siegall has helped the company to make successful breakthroughs in cancer research. Clay has a genuine desire to assist cancer patients. It is for this reason that Dr. Clay has zeroed in on developing viable cancer drugs to lengthen the lives of cancer patients. Under Siegall’s visionary leadership, the company was able to develop the first antibody-drug conjugates known as ADCETRIS.

About Clay Siegall

Clay Siegall is a revered scientist. Over the years, he has specialized in targeted cancer therapies. Clay is one of the founders of Seattle Genetics, which was established in 1998. He serves as the CEO and president of company. In addition, Clay is the chairman of the board. He founded the company on the foundation of rigorous research, scientific innovation, drug development and passion for assisting patients. Presently, Siegall is leading the company in developing a pipeline of proprietary ADCs for cancer treatment.

Over the years, Clay has helped Seattle Genetics to enter into several strategic partnerships with GlaxoSmithKline, AbbVie, and Genentech for its ADC technology. These licenses have generated over $350 million. Siegall has also guided the firm in capital-raising activities. To this end, he has secured more than $1.2 for the corporation through private and public financing.